165 related articles for article (PubMed ID: 30098763)
1. Metabolic signature of squamous cell carcinoma of the head and neck: Consequences of TP53 mutation and therapeutic perspectives.
Wilkie MD; Lau AS; Vlatkovic N; Jones TM; Boyd MT
Oral Oncol; 2018 Aug; 83():1-10. PubMed ID: 30098763
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations in head and neck cancer cells determine the Warburg phenotypic switch creating metabolic vulnerabilities and therapeutic opportunities for stratified therapies.
Wilkie MD; Anaam EA; Lau AS; Rubbi CP; Jones TM; Boyd MT; Vlatković N
Cancer Lett; 2020 May; 478():107-121. PubMed ID: 32113989
[TBL] [Abstract][Full Text] [Related]
3. The role of CIP2A as a therapeutic target of rapamycin in radioresistant head and neck cancer with TP53 mutation.
Kim SH; Lee WH; Seong D; An JH; Je HU; Nam HY; Kim SY; Kim SW; Han MW
Head Neck; 2019 Sep; 41(9):3362-3371. PubMed ID: 31268585
[TBL] [Abstract][Full Text] [Related]
4. Translational Research: A Future Strategy for Managing Squamous Cell Carcinoma of the Head and Neck?
Caponigro F; Ionna F; Scarpati GDV; Longo F; Addeo R; Manzo R; Muto P; Pisconti S; Leopaldi L; Perri F
Anticancer Agents Med Chem; 2018; 18(9):1220-1227. PubMed ID: 29637868
[TBL] [Abstract][Full Text] [Related]
5. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C
Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337
[TBL] [Abstract][Full Text] [Related]
6. Tumour metabolism in squamous cell carcinoma of the head and neck: an in-vitro study of the consequences of TP53 mutation and therapeutic implications.
Wilkie M; Lau A; Vlatkovic N; Jones T; Boyd M
Lancet; 2015 Feb; 385 Suppl 1():S101. PubMed ID: 26312831
[TBL] [Abstract][Full Text] [Related]
7. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck.
Nylander K; Dabelsteen E; Hall PA
J Oral Pathol Med; 2000 Oct; 29(9):413-25. PubMed ID: 11016683
[TBL] [Abstract][Full Text] [Related]
8. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.
Tinhofer I; Budach V; Saki M; Konschak R; Niehr F; Jöhrens K; Weichert W; Linge A; Lohaus F; Krause M; Neumann K; Endris V; Sak A; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baumann M;
Eur J Cancer; 2016 Apr; 57():78-86. PubMed ID: 26896955
[TBL] [Abstract][Full Text] [Related]
9. Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies?
Zilberg C; Lee MW; Kraitsek S; Ashford B; Ranson M; Shannon K; Iyer NG; Ch'ng S; Low TH; Palme C; Clark J; Gupta R; Yu B
J Clin Pathol; 2020 Jan; 73(1):17-22. PubMed ID: 31300530
[TBL] [Abstract][Full Text] [Related]
10. p53 in head and neck cancer: functional consequences and environmental implications of TP53 mutations.
Peltonen JK; Helppi HM; Pääkkö P; Turpeenniemi-Hujanen T; Vähäkangas KH
Head Neck Oncol; 2010 Dec; 2():36. PubMed ID: 21159183
[TBL] [Abstract][Full Text] [Related]
11. Frameshift events predict anti-PD-1/L1 response in head and neck cancer.
Hanna GJ; Lizotte P; Cavanaugh M; Kuo FC; Shivdasani P; Frieden A; Chau NG; Schoenfeld JD; Lorch JH; Uppaluri R; MacConaill LE; Haddad RI
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467336
[TBL] [Abstract][Full Text] [Related]
12. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
13. Loss of MTBP expression is associated with reduced survival in a biomarker-defined subset of patients with squamous cell carcinoma of the head and neck.
Vlatković N; El-Fert A; Devling T; Ray-Sinha A; Gore DM; Rubbi CP; Dodson A; Jones AS; Helliwell TR; Jones TM; Boyd MT
Cancer; 2011 Jul; 117(13):2939-50. PubMed ID: 21692053
[TBL] [Abstract][Full Text] [Related]
14. Novel prognostic clinical factors and biomarkers for outcome prediction in head and neck cancer: a systematic review.
Budach V; Tinhofer I
Lancet Oncol; 2019 Jun; 20(6):e313-e326. PubMed ID: 31162105
[TBL] [Abstract][Full Text] [Related]
15. Targeting metabolic pathways for head and neck cancers therapeutics.
Yamamoto M; Inohara H; Nakagawa T
Cancer Metastasis Rev; 2017 Sep; 36(3):503-514. PubMed ID: 28819926
[TBL] [Abstract][Full Text] [Related]
16. mTOR Signalling in Head and Neck Cancer: Heads Up.
Tan FH; Bai Y; Saintigny P; Darido C
Cells; 2019 Apr; 8(4):. PubMed ID: 30970654
[TBL] [Abstract][Full Text] [Related]
17. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma.
Koch WM; Brennan JA; Zahurak M; Goodman SN; Westra WH; Schwab D; Yoo GH; Lee DJ; Forastiere AA; Sidransky D
J Natl Cancer Inst; 1996 Nov; 88(21):1580-6. PubMed ID: 8901856
[TBL] [Abstract][Full Text] [Related]
18. Clinical update on head and neck cancer: molecular biology and ongoing challenges.
Alsahafi E; Begg K; Amelio I; Raulf N; Lucarelli P; Sauter T; Tavassoli M
Cell Death Dis; 2019 Jul; 10(8):540. PubMed ID: 31308358
[TBL] [Abstract][Full Text] [Related]
19. Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
Yun M; Choi AJ; Lee YC; Kong M; Sung JY; Kim SS; Eun YG
J Exp Clin Cancer Res; 2018 Oct; 37(1):264. PubMed ID: 30376862
[TBL] [Abstract][Full Text] [Related]
20. The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer.
Coaxum SD; Tiedeken J; Garrett-Mayer E; Myers J; Rosenzweig SA; Neskey DM
Oncotarget; 2017 Apr; 8(14):22991-23007. PubMed ID: 28160562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
